In the treatment of non-complicated type B aortic dissection (TBAD), disagreement exists between Chinese and Western academic associations, and previous European and American guidelines emphasized conservative treatment. However, with the increase of long-term follow-up data of TBAD patients and the extensive application and improvement of endovascular techniques, the effective role of TEVAR in non-complicated TBAD has gradually been recognized by Western academic community, and has been elaborated in this year's American STS/AATS guideline. Therefore, this paper interprets the relevant parts of the guideline for discussion among professional scholars.